Obesity
Conditions
Interventions
Semaglutide intervention group:Semaglutide intervention
Sponsors
Xi'an Jiaotong University Second Affiliated Hospital
Eligibility
Sex/Gender
All
Age
18 Years to 44 Years
Inclusion criteria
Inclusion criteria: (1) 18-44 years old (adult, youth) with more than 1 failed experience of diet and exercise weight loss, both men and women; (2) BMI >=30kg/m^2 [weight (kg)/height (m)^2] (3) Patients with a BMI of 30-27 kg/m^2 and at least one obesity complication (hypertension, dyslipidemia, Obstructive sleep apnea or cardiovascular disease) (4) HbA1c <= 6.5% during the screening period, and fasting blood glucose value <= 6.1mmol/L and 2-hour postprandial blood glucose <= 11.1mmol/L on the day of screening; (5) Have not used traditional Chinese medicine and western medicine to control weight loss within 6 months; (6) A detailed understanding of the nature, significance, possible benefits, possible inconveniences and potential dangers of the trial; (7) Understand the study procedures, voluntarily participate in this study and sign the informed consent form.
Exclusion criteria
Exclusion criteria: (1) People with diabetes mellitus, including (type 1 diabetes, type 2 diabetes, monogenic mutant diabetes, diabetes caused by pancreatic damage or other secondary diabetes mellitus), glycosylated hemoglobin A1c (HbA1c), >= 6.5% (48 mmol/mol), fasting blood glucose value =grade III), etc., or have received interventional therapy or implanted coronary stents, and the systolic blood pressure cannot be controlled below 160mmHg after using 3 kinds of antihypertensive drugs); (6) Treated or untreated organ system tumors (except localized basal cell carcinoma of the skin) within the past 5 years, regardless of whether they have evidence of local recurrence or metastasis; (7) Gastrointestinal diseases that affect food digestion and absorption (such as severe diarrhea, constipation, irritable bowel syndrome, inflammatory bowel disease, active peptic ulcer, acute cholecystitis, etc.) Severe diarrhea refers to watery stools 3 or more times a day and lasts for 3 days or more, and severe constipation refers to 2 or less bowel movements per week, accompanied by difficulty in defecation; (8) Presence of any hematologic disease that may interfere with HbA1c measurement, with severe infection, severe anemia, neutropenia; (9) History of previous intestinal segment resection, or history of other gastrointestinal surgery (such as cholecystectomy) within 1 year before screening, or history of other non-gastrointestinal surgery within half a year; (10) History of neuropsychiatric system abnormalities or drug abuse; (11) Those who have used weight-controlled drugs (including weight loss drugs), corticosteroids and other hormonal drugs (including oral, intramuscular or intravenous systemic administration, non-gastrointestinal administration or intra-articular administration) within 3 months before admission or plan to use weight control drugs (including weight loss drugs) during the trial; (12) Severe liver and kidney dysfunction, or alanine aminotransferase (ALT) or aspartate aminotransferase (AST) >=2.5×ULN, serum creatinine =5kg) (14) Those with a history of active substance abuse and/or alcoholics [alcohol intake >>40 g/day for men, 20 g/day for women, 40g of alcohol is about 1000mL of beer (6 degrees), or 500 mL of red or rice wine (12 degrees), or 100 mL of white wine (50 degrees)]; (15) Pregnant or lactating women, or women who are expected to have childbearing needs within one and a half years; (16) Any situation that the investigator considers unsuitable to participate in this study.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Weight; | — |
Countries
China
Contacts
Public ContactNing Wang
The Second Affiliated Hospital of Xi'an Jiaotong University
Outcome results
None listed